Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318151 | 1.00 | SHMT1 (0.42) | SHMT1GALR3ALDH1A1LMNANR2F2 | |
| SCHEMBL6317231 | 0.89 | RORB (0.41) | SHMT1KIF11PPARA | |
| SCHEMBL6317221 | 0.89 | RORB (0.41) | SHMT1KIF11PPARA | |
| SCHEMBL6318428 | 0.89 | KIF11 (0.38) | SHMT1KIF11PPARA | |
| SCHEMBL6326003 | 0.88 | KIF11 (0.36) | SHMT1KIF11PPARATMEM97SIGMAR1 | |
| SCHEMBL6318551 | 0.88 | KIF11 (0.36) | SHMT1KIF11PPARATMEM97SIGMAR1 | |
| SCHEMBL6317258 | 0.88 | CYP3A4 (0.39) | SHMT1KIF11 | |
| SCHEMBL6318056 | 0.87 | KIF11 (0.37) | SHMT1KIF11PPARA | |
| SCHEMBL6318059 | 0.87 | KIF11 (0.37) | SHMT1KIF11PPARA | |
| SCHEMBL6316934 | 0.87 | PPARA (0.40) | SHMT1KIF11PPARATMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| EP-1395571-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Shire Biochem Inc. (CA) | 2004-03-10 | — | — | EP | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
| WO-2002100846-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | SHMT1 2213/4885GALR3 3791/4885ALDH1A1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.